Format

Send to

Choose Destination
J Bone Metab. 2019 Feb;26(1):39-44. doi: 10.11005/jbm.2019.26.1.39. Epub 2019 Feb 28.

Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration.

Author information

1
Department of Orthopaedic Surgery, Yeungnam University Medical Center, Daegu, Korea.
2
Department of Orthopaedic Surgery, Soonchunhyang University Hospital Cheonan, Cheonan, Korea.
3
Department of Orthopaedic Surgery, Soonchunhyang University Hospital Seoul, Seoul, Korea.
4
Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.

Abstract

Background:

Bisphosphonate (BP) is an effective drug for the prevention and treatment of osteoporosis. However, gastrointestinal distress caused by BP is a well-known side effect for low compliance. The aim of our study was to compare the 1-year persistence, compliance and T-scores between the aperitif medication group and the postprandial medication group.

Methods:

Three hundred patients were included in this study to determine their persistence and compliance with the prescribed daily BP (Maxmarvil®, alendronate 5 mg and calcitriol 0.5 µg; YuYu Pharm) following distal radius fractures. Patients in Group 1 (aperitif medication) were asked to adhere to the general guidelines for BPs before breakfast. Patients in Group 2 (postprandial medication) were recommended medication after breakfast. We compared the persistence and compliance of this daily BP therapy using the medication possession ratio (MPR) and T-scores between the 2 groups after 1 year.

Results:

Bone mineral density in hip and lumbar spine was improved significantly in 2 groups (P<0.001). Significant differences existed between 2 groups, including 73 of 150 patients (48.7%) in Group 1, and 111 of 150 patients (73.3%) in Group 2 for 1-year persistence (P=0.001). The mean MPR is 0.66 in Group 1 (range, 0.50-0.86) and 0.71 in Group 2 (range, 0.54-0.87). A significant difference was detected between the 2 groups (P=0.002).

Conclusions:

Postprandial administration improved persistence and compliance with daily BP therapy, resulting in better clinical outcomes.

KEYWORDS:

Aperitif; Bisphosphonate; Compliance; Daily; Persistence; Postprandial

Supplemental Content

Full text links

Icon for The Korean Society for Bone and Mineral Research Icon for PubMed Central
Loading ...
Support Center